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PS Gla domain may contain functionally important structural
determinants that are not present in prothrombin and possibly
in other vitamin K-dependent proteins.
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Activated protein C (APC) is inhibited primarily by the serine
proteinase inhibitors a1-antitrypsin (a1AT) [1], protein C
inhibitor (PCI) [1], and a2-macroglobulin [2,3]. We recently
demonstrated in a large French–Canadian kindred that over
half of the variance in the APC–a1AT complex and APC–PCI
complex plasma concentrations could be attributed to genetic
inﬂuences [4]. As this thrombophilic kindred has protein C
deﬁciency and these complexes reﬂect the level of APC, we used
variance component linkage analysis to identify quantitative
trait loci that might explain the inherited component of the
variance in APC–a1AT and APC–PCI plasma concentrations.
The study subjects were members of the French–Canadian
kindred. The ascertainment, evaluation, and blood collection
of all family members were described previously [5], as well as
the methods for measuring plasma concentrations of APC–
a1AT complex, APC–PCI complex, protein C activity, and
prothrombin activation fragment 1.2 (F1.2) [4]. a1AT plasma
concentrations were measured by the Beckman–Coulter Image
system, and PCI plasma concentrations were measured using a
kit from Enzyme Research Laboratories (South Bend, IN,
USA). This study was approved by the Human Experimenta-
tion Committee of the University of Vermont College of
Medicine, Burlington, Vermont, USA. All participating sub-
jects gave informed consent. For the current analysis, we
included individuals for whom we had plasma concentrations
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of APC–a1AT and APC–PCI complex, and genotyping data
(n ¼ 148). We excluded individuals on coumarin derivatives
(n ¼ 9), women who were pregnant at the time of the blood
draw (n ¼ 2), and women for whomwe had no information on
the use of female hormones (n ¼ 2). Genotyping was per-
formed with 375 autosomal markers as described by Hasstedt
et al. [6]. The probability of identity by descent (IBD) was
estimated using the linkage analysis package Loki [7]. Addi-
tional markers for ﬁne mapping were genotyped using an
ABI310 or 3100 at the Vermont Cancer Center DNA analysis
facility, and selected markers were run byDecode Genetics Inc.
(Reykjavik, Iceland). Using Sequential Oligogenic Linkage
Analysis Routines (SOLAR) [8] version 2.1.4, we performed
variance component linkage analysis. All (transformed) levels
were assumed to be distributed as a multivariate normal
density. The parameters for heritability (h2), household effect
(c2), and heritability that was contributed to a speciﬁc genomic
location (q2) as well as the effects of the covariates were
estimated simultaneously using maximum likelihood analysis.
LOD scores were computed as the log10 likelihood for q
2
estimated to q2 ¼ 0. As proposed by Lander and Kruglyak [9],
we deﬁned signiﬁcant linkage as statistical evidence expected to
occur 0.05 times in a whole genome scan (probability 5%;
LOD score ‡3.3) and suggestive linkage as statistical evidence
that would be expected to occur one time at random in a whole
genome scan (LOD score between 1.9–3.3). The 95% conﬁd-
ence interval (CI) was determined by the points on the curve
deﬁned by dropping the lod score by one unit.
A total of 135 subjects were included in the analysis. Subjects
were from 92 households with a mean of 1.4 individuals per
household (range 1–4 individuals). The mean age at the blood
draw was 28 years (range 1–75 years), 75 participants were
women (56%), 28 (21%) carried the protein C 3363C insertion,
28 (21%) carried the prothrombin G20210A mutation (one
was homozygous) and eight (6%) had a history of conﬁrmed
venous thrombosis. Variance component linkage analysis on
plasma concentrations of APC–a1AT complex revealed LOD
scores above one for chromosomes 13, 14, and 19 (adding age,
sex, and use of female hormones as covariates to the model).
LOD scores suggestive of linkage were found on chromosome
19p13.2 (LOD score 3.1 at 35 cM; 95% CI 25–40 cM, nearest
marker D19S586) and on chromosome 13q14 (LOD score 2.0
at 56 cM; 95% CI 49–68 cM, nearest marker D13S800)
(Table 1). However, adding markers in the area under the
peak at chromosome 19 decreased the LOD score to 2.2
(Table 1). Eliminating levels of individuals with a conﬁrmed
history of thrombosis decreased the LOD score on chromo-
some 13 to 1.6 and on chromosome 19 to 1.9 (Table 1).
Inclusion of protein C status as a covariate in themodel did not
alter the lod scores (Table 1). For plasma concentrations of
APC–PCI complex LOD scores above one were found on
chromosomes four and 11 (adding age, sex, and use of female
hormones as covariates in the model). The highest LOD score
was found on chromosome 11q25 (LOD score 2.2 at 141 cM;
95% CI 126–147, nearest marker D11S1304) (Table 1). The
LOD score increased to 2.9 after eliminating the levels of
individuals with a conﬁrmed history of venous thrombosis
(Table 1). Adding markers in the area under the peak
decreased the LOD score on chromosome 11 to 2.3 (Table 1).
The LOD score remained 2.3 after removal of the effect of
protein C status in the model (Table 1). No evidence for
linkage was observed for protein C, F1.2, a1AT, and PCI
plasma concentrations at the identiﬁed ﬁne-mapped peaks on
chromosomes 11 and 19.
We have presented suggestive evidence for quantitative trait
loci linked to the variance in plasma concentrations of APC–
PCI andAPC–a1AT complexes, which reﬂect the activity of the
protein C system. In the regions showing suggestive linkage
evidence, no speciﬁc candidate genes were identiﬁed. Thus, it
appears that yet-to-be-determined novel genes may play a role
in modulating APC activity. The only other report of
quantitative trait loci associated with the activity of the protein
C systemwas that of Soria et al. [10], which reported a locus on
chromosome 18 that inﬂuences variation in the APC resistance
phenotype.
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Table 1 Results of the variance component linkage analysis on plasma concentrations of APC–a1AT and APC–PCI for locations showing initially a LOD
score above 1.9
APC-a1AT (cM)
[APC-PCI (cM)]
chromosme 11Chromosome 13 Chromosome 19
Initial LOD score* (location) 2.0 (56) 3.1 (35) 2.2 (141)
Removal eﬀect thrombosis (location) 1.6 (56) 2.4 (35) 2.9 (141)
Removal eﬀect PC status (location) 1.9 (57) 3.0 (35) 2.1 (141)
LOD score after ﬁnemapping* (location) N/a 2.2 (29) 1.8 (140)
Removal eﬀect thrombosis (location) N/a 1.9 (27) 2.3 (140)
Removal eﬀect PC status (location) N/a 2.2 (29) 2.3 (140)
APC, activated protein C; a1AT, a1-antitrypsin; PCI, protein C inhibitor; PC, protein C mutation; N/a, not applicable.
*With removal of the eﬀect of age, sex, and the use of female hormones.
Location in cM on the Marshﬁeld map.
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We read with interest the paper by Imberti et al. [1] and agree
with their views regarding the need for documentation of the
length of implantation time for retrievable vena cava ﬁlters.
The authors report an average implantation time of 123 days
with a maximum of 345 days.
In our own recent experience (21 ﬁlters implanted and only
12 already extracted at the moment), the longest implantation
time was 485 days in a 35-year-old man in which ﬁlter
implantation was indicated for proximal deep vein thrombosis
in a context of acute alcoholic pancreatitis with abdominal
bleeding. The patient was momentarily lost for follow-up after
hospital discharge but came back to our institution 15 months
later. Decision to make an attempt at removing the ﬁlter was
taken despite this long delay because of his poor compliance for
any kind of follow-up and the absence of permanent risk factor
for thromboembolic disease. Correct position of ﬁlter and
permeability of vena cava were conﬁrmed by computed
tomographic scan prior to the procedure. The ﬁlter was easily
extracted using the procedure recommended by the manufac-
turer without any mechanical damage to the venous wall. The
examination of the ﬁlter ex vivo revealed only minor clots in the
legs. The implantation time in our patient is, to our knowledge,
the longest described in the literature [1,2].
As with other authors [3], we believe that the interest of using
such temporary ﬁlters increases when the expected period of
implantation time can be counted in weeks or months rather
than in days, and agree that further scientiﬁc evidence is needed
[4] before such long implantation durations, as in the case we
report, should be encouraged. In the mean time, we feel that
such individual experience driven by unusual clinical situations
should be reported in order to make the information available.
A large multicenter register could be the most efﬁcient way for
this purpose.
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